Collins Stewart Reiterates Sell and PT of $9 on Amylin Pharmaceuticals

by Emily Austin, Benzinga Staff Writer
June 27, 2011 9:21 AM | 8 seconds read |
Collins Stewart reiterated its Sell rating and PT of $9 on Amylin Pharmaceuticals AMLN. On Friday, Amylin finished the day at $11.83.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: ReiterationAnalyst RatingsAmylin PharmaceuticalsBiotechnologyCollins StewartHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!